NVIDIA’s $250M, five-year compute donation funds UK agentic AI safety research, with implications for how GMP teams validate and govern autonomous AI.
News|Articles|May 2, 2005
- Pharmaceutical Technology-05-02-2005
- Volume 29
- Issue 5
Automating HPLC and GC Analytical Method Validation
Author(s)Patrick Lukulay, Richard Verseput
A newly developed software program transforms written SOPs for all required analytical method validation experiments into transferable automated templates, integrating individual activities and technologies under one platform.
Advertisement
Articles in this issue
over 21 years ago
New Vaccine Technologies Carry and Deliver by Kaylynn Chiarelloover 21 years ago
GenerationNextover 21 years ago
New Vaccine Technologies Carry and Deliverover 21 years ago
May 2005over 21 years ago
Bar Coding Deadline Loomsover 21 years ago
In the Spotlight - May 2005over 21 years ago
New FDA Policies Shape Pharma Development and Productionover 21 years ago
Price MattersAdvertisement
Related to this article
MASH and cardiomyopathy AI collaboration: AstraZeneca pays insitro $40M upfront for target discovery, then leads clinical development and CMC planning.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FDA Rare Disease Framework Puts CMC Review in Scope
2
Rare Pediatric PRVs: Manufacturing Strategies for Expedited Approval, Part 1
3
Manufacturing Intelligence: What FDA's Real-World Use Case Database Means for CMC
4
PharmTech AI Pulse Check: AI Watermark Vulnerability
5